Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Second IVIg Dose in GBS Patients with Poor Prognosis (SID-GBS)
2008-005659-83Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Sep 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of immune globulin in Guillain-Barré syndrome (GBS) (2 arms), sponsored by Erasmus MC. Primary endpoint: Functional outcome at 4 weeks. Started Sep 2009; status: active.
02
Drugs
immune globulin
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on 2008-005659-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005659-83.